ResearcherUniversity of Wisconsin–MadisonNo recent work listed

Haiming Luo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6226-5800; OpenAlex author ID A5110297229. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper

Papers 2

ImmunoPET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer with a Dual-Labeled Bispecific Antibody Fragment. Co-author DOI 10.1021/acs.molpharmaceut.6b01123 ↗
Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-15-2054 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Christopher G. England · 2 shared papers, 2016–2017 · strength 0.12
- Paper ImmunoPET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer with a Dual-Labeled Bispecific Antibody Fragment. DOI 10.1021/acs.molpharmaceut.6b01123 ↗
- Paper Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-15-2054 ↗
Weibo Cai · 2 shared papers, 2016–2017 · strength 0.12
- Paper ImmunoPET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer with a Dual-Labeled Bispecific Antibody Fragment. DOI 10.1021/acs.molpharmaceut.6b01123 ↗
- Paper Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-15-2054 ↗
Reinier T. Hernandez · 1 shared paper, 2016 · strength 0.06
- Paper Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-15-2054 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.